• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
CLDX

CLDX

Celldex Therapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD29.77

+0.87 (+3.01%)

Rating:C

Company Profile

CEO

Anthony S. Marucci

IPO Date

1986-05-15

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$29.02

Prev. Close

$28.90

Day Low

$28.90

Day High

$29.86

52W Low

$19.25

52W High

$35.79

Market Cap

$1.98B

Volume

0.87M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

54.2%

Avg Negative

2.4%

Avg Neutral

43.7%

News Feed

Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research·8/5/2021·↑ positive

How Good Were Celldex Therapeutics' Latest Clinical Results?

The Motley Fool·7/24/2021·↑ positive

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewsWire·7/16/2021
·↑ positive

Celldex Therapeutics Raises $250M Via Equity To Support Development Of Skin Disease Candidate

Benzinga·7/14/2021·↑ positive

Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock

GlobeNewsWire·7/13/2021·↑ positive

Why Celldex Therapeutics Stock Is Jumping Again Today

The Motley Fool·7/13/2021·↑ positive

Celldex's Latest Data For Chronic Inducible Urticaria Drug Is Only The Beginning

Seeking Alpha·7/13/2021·↑ positive

Why Celldex Therapeutics Stock Is Skyrocketing Today

The Motley Fool·7/12/2021·↑ positive

CLDX Stock Increases Over 30% Pre-Market: Why It Happened

Pulse2·7/12/2021·↑ positive

Celldex Stock Surges As It Touts Early-Stage Skin Disease Study Win For CDX-0159

Benzinga·7/12/2021·↑ positive